Highlights from the Afghanistan and Colombia reports are below.Meeting with mullahs in Afghanistan: Addressing Cultural Competence in Humanitarian ActionIn Afghanistan, led the lead researcher Donini more than 50 interviews and 18 focus groups in rural and urban areas to discover how community members, aid workers and government officials of humanitarian work in the country conducted post 9/11. He found that a major obstacle threatens humanitarian action the gap in perception between NGOs, politicians, media and people in Afghanistan.
In order that affect the that affect the humanitarian action over the next decade, researchers from the Feinstein International Center at Tufts University, traveled to Afghanistan, Colombia, Burundi, Liberia, and northern Uganda A new report of this effort, and counter terrorisme Humanitarian Agenda 2015:. Principles, Power and perceptions identified large gaps between the current practice of humanitarian aid and the local. Perceptions of beneficiaries in crisis situations , it was if these gaps are not addressed, they will increasingly difficult challenges for the success of international humanitarian aid during the next decade set.Disclosure information This document includes statements have nothing to do strictly historical facts , each of which his forward-looking statements the purposes of the Securities Litigation Reform Act of 1995. We will expect words, utilize plans, awaits and similar expressions to identify forward-looking statements we. Inconvenient certain known and unknown risks and uncertainties that can cause our actual results to, performance or achievements of differ materially from the expressed or implied by forward-looking statements. Whilst it is impossible to know or predictions all of issues, this may, among other things, of the inherent uncertainty of the timing and success and costs with with research, development, regulatory approval and commercialization of our products and product candidates including those associated effect that clinical Degree no and go planned, product that proof in early studies no highly promising, effectiveness and safety in bigger ,, data and clinical studies about our products and drug candidates will be unfavorable, our products will not receive marketing approval of regulators or, if authorized, not to obtain enough market adoption the be justified development and commercialization of costs, us, of our employees and any other may be to identify side effects, clinical trials which on the market, and and concerns over marketed products, non on following tests or other Things to us, governmental regulators, other undertakings and organizations or otherwise, and whether or not scientific justification, may about recalls, redemption of marketing authorization, product reformulation, supplementary pre-clinical test and conduct of clinical trials, changes in the marking of the product, the necessity for additional marketing applications, falling sales or other adverse..